Early leukemia and lymphoma remissions in cats and dogs

June 7, 2022

This article was written by Dr. Omer Rashid, DVM, MSc Parasitology and published in Innovative Veterinary Care Journal.

---

Time is of the essence in prescribing the right drug for lymphoma and leukemia. Artificial Intelligence can help.

Get straight to business by opting for drugs that work.

The prognosis for leukemia and lymphoma in dogs and cats is traditionally quite low. Because these cancers are invasive by nature, they should be confronted at an early stage to increase remission rates.

Veterinarians are bound to encounter situations in which particular cancer drugs prove themselves ineffective in certain patients. This is not, of course, the fault of the clinicians, as the drugs are recommended on the basis of their known mechanism of action. But it is a fact that animals with different genetic makeups respond differently to medication – and this phenomenon can cause failed treatments, elapsed time, and wasted money.

The time it takes to find the right drug can take a toll on the animal. The chances are high that you might use medicines that end up showing little to no efficacy. As a result, the cancer gets room to progress without inhibition during the course of treatment — jeopardizing the animal’s life. This makes traditional cancer treatment akin to going to war without being sure of having the right weapons.

ImpriMed presents a novel solution

ImpriMed was founded with a vision to counter cancer. The company’s aim was not to manufacture groundbreaking drugs to overcome the disease. Instead, their cancer panacea involved an innovative idea – they used existing clinical data and advanced algorithms to pinpoint the most viable medicine for individual patients.

Up till now, more than 200 veterinary oncologists have ordered personalized drug response prediction profiles from ImpriMed. And many clinicians have become a witness to success stories that speak volumes about the efficacy of ImpriMed’s prediction profile regarding leukemia and lymphoma.

ImpriMed is unique because it doesn’t only depend on information about breed, age, or sex to chalk out a drug response probability chart. It works by taking live cells from patients and testing responses to different cancer drugs. The resulting data is then subjected to specialized AI that uses proprietary clinical data to create a personalized drug response profile.

Choosing the right drug at the very beginning of treatment can be a make-or-break proposition — and ImpriMed is there to help you out. The science behind their solution has been validated by studies published in reputable veterinary journals. When you work with ImpriMed, you are taking a big step toward making the right treatment choice, and saving an animal’s life.

You can expect to receive a personalized drug response prediction profile for your patient after only three to seven days of sample collection. ImpriMed also offers other services, such as immunoprofiling using flow cytometry and PCR for antigen receptor rearrangements, flow cytometry only, and PCR for antigen receptor rearrangements only.

www.ImpriMedicine.com

In the News

How Artificial Intelligence Is Revolutionising Cancer Care for Pets

Pets Magazine
Learn More →

Artificial Intelligence Takes on Cancer: The Only AI Dr. Karyn Doesn’t Hate

Dogster
Learn More →

Comparative Oncology: Advances in Cancer Care from Pets to Humans

Pharmacy Times
Learn More →

Cancer Treatment Gets Personal: How Artificial Intelligence Is Taking the Guesswork Out of Common Canine Cancers

Dogster
Learn More →

Ilona Holcomb on How ImpriMed’s AI is Transforming Cancer Treatment for Pets and Humans

Biopharma Boardroom
Learn More →

From Dogs to Humans: AI-Powered Drug Response Prediction Technology Demonstrates Improved Clinical Outcomes in Oncology

Pharmacy Times
Learn More →

ImpriMed unveils cancer treatment forecast technology

MobiHealthNews
Learn More →

New research evaluates flow cytometry and PARR as diagnostic support for feline lymphoma

American Animal Hospital Association NEWStat®
Learn More →

Cell-sizing method for high-accuracy feline lymphoma characterisation in veterinary sciences

Veterinary Practice
Learn More →

Flow cytometry and clonality evaluation are effective for characterizing feline lymphoma

DVM360
Learn More →

ImpriMed: Providing Personalized Medicine For Pets With Blood Cancer Diseases In A $1+ Billion Market

Pulse 2.0
Learn More →

New AI Tool Guides Canine Cancer Treatment

Today's Veterinary Business
Learn More →

Artificial intelligence poised to transform veterinary care

AVMA News
Learn More →

New AI service offers personalized drug response predictions for canine patients with cancer

DVM360
Learn More →

Dog cancer treatment ImpriMed aims to expand its AI technology into human oncology

TechCrunch
Learn More →

ImpriMed’s Transformative, Personal Approach to Canine Cancer Treatment

USA Today
Learn More →

Data Science Can Markedly Improve Cancer Treatment Outcomes — ImpriMed Shows You How

Innovative Veterinary Care Journal
Learn More →

How ImpriMed Can Help Increase Cancer Remissions, Grow Your Reputation and Level Up Your Revenue

Innovative Veterinary Care Journal
Learn More →

ImpriMed: A Breath of Fresh Air for Traditionally Onerous Cancer Treatment Journeys

Innovative Veterinary Care Journal
Learn More →

ImpriMed: Revolutionizing Canine Cancer Treatment with Precision and Personalization

International Business Times
Learn More →

New AI Technology From ImpriMed Helps Improve Cancer Treatment Success Rates in Your Practice…and Fosters Better Relationships

Innovative Veterinary Care Journal
Learn More →

The latest and greatest in canine oncology treatment

DVM360
Learn More →

Get Rid of Your Cancer Treatment Frustrations

Innovative Veterinary Care Journal
Learn More →

Meet the 7 startups Mayo Clinic just welcomed to its AI accelerator

MedCity News
Learn More →

Be sure to improve your cancer treatment outcomes

Innovative Veterinary Care Journal
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 3)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 2)

One Million by One Million
Learn More →

Thought Leaders in Artificial Intelligence: ImpriMed CEO Sungwon Lim (Part 1)

One Million by One Million
Learn More →

Technological advancement makes cancer treatment easier

Innovative Veterinary Care Journal
Learn More →

Novel veterinary oncologic treatments and diagnostics

dvm360
Learn More →

AI’s Computing Power Could Make Fusion Energy Practical

Lifewire
Learn More →

Don't Guess Your Pet's Condition, Treat It with ImpriMed

Startup to Follow
Learn More →

Interview with ImpriMed CEO & Co-Founder Sungwon Lim

IdeaMensch
Learn More →

This Test Might Make All The Difference When Fighting Lymphoma

Canine Cancer Alliance
Learn More →

ImpriMed: Fighting Cancer — From Dogs To Humans

Startup Thread
Learn More →

At Pear demo day, a who’s who of VCs, and plenty of fresh ideas

TechCrunch
Learn More →